Vertex to acquire Alpine for $65/share (~$4.9B); deal expected to close Q2 2024

ALPINE IMMUNE SCIENCES, INC.

Total equity value ~$4.9B; Vertex will pay $65 per share in cash.
Alpine’s lead drug povetacicept (dual BAFF/APRIL antagonist) showed best-in-class potential in IgA nephropathy; Phase 3 planned H2 2024.
Stockholders owning ~25.5% of shares have agreed to tender; termination fee of $173M payable by Alpine under certain conditions.
Transaction unanimously approved by both boards; expected to close in Q2 2024, subject to HSR and tender of majority of shares.
Alpine’s pipeline includes studies in membranous nephropathy, lupus nephritis, and autoimmune cytopenias.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ALPINE IMMUNE SCIENCES, INC. entered into Agreement and Plan of Merger with Vertex Pharmaceuticals Incorporated valued at $65.00 per share in cash, aggregate termination fee of $173 million (effective 2024-04-10).

Action: entry
Agreement: merger
Counterparty: Vertex Pharmaceuticals Incorporated
Value: $65.00 per share in cash, aggregate termination fee of $173 million
Effective: 2024-04-10

Exact text from the filing

On April 10, 2024, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“ Parent ”), Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), and Alpine Immune Sciences, Inc., a Delaware corporation (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”).

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001193125-24-091936

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.